Эбрантил Drug photo

The description is actual on 04.03.2015

  • Latin name: Ebrantil
  • ATH code: C02CA06
  • Active ingredient: Urapidil (Urapidilum)
  • Producer: Nycomed GmbH, Takeda GmbH (Germany)


Ebrantil in the form of solution for in/in includes an urapidil a hydrochloride as active making. Additional components: propylene glycol, dihydrophosphate sodium a dihydrate, hydrophosphate sodium a dihydrate, the water purified.

urapidit active agent of capsules. Auxiliary components: sugar krupka, talc, fumaric acid, ethyl cellulose, gipromelloza phthalate, methacrylic acid and methylmethacrylate copolymer, diethyl phthalate, gipromelloza, stearic acid. The cover of capsules includes: gelatin, dye ferrous oxide yellow, titanium dioxide, water. The sugar krupka contains sucrose, water and corn starch.

Release form

Is issued in the form of transparent solution for internal introduction and gelatinous capsules on 30 and 60 mg. Capsules contain yellow granules.

Pharmacological action

Ebrantil represents medicine with hypotensive action.

Pharmacodynamics and pharmacokinetics

Mechanism of effect of drug central and peripheral. Ebrantil inhibits postsynaptic alfa1-adrenoceptors that leads to reduction of peripheric resistance. It also influences the central mechanism of maintenance of a vascular tone and is characterized by weak beta and adrenoceptor blocking properties. ChSS and cordial emission do not change. Increase of low cordial emission because of reduction of vascular resistance is possible. Medicine inhibits vasoconstriction which is provoked by alfa2-adrenoceptors.

It is balanced reduces the GARDEN and DAD, reducing peripheric resistance. Reduces loads of heart and increases efficiency of cordial reduction. In the absence of arrhythmia the reduced minute volume of heart increases.

In a nervous system active ingredient of drug influences activity of a vasomotor center because of what there is no reflex change of a tone of a sympathetic nervous system.

Concentration of solution after introduction in a dosage of 25 mg decreases in 2 stages. At first there is a fast reduction, and then – slow. Time of distribution of medicine – about 35 minutes.

The main part of active agent is split in a liver. Its main metabolite – hydroxylated in the fourth provision of benzene ring derivative.

About 60% of the operating component and its metabolites are excreted through kidneys. The rest in the form of metabolites is removed through intestines.

Drug elimination half-life after intravenous administration – about 3 hours. Extent of communication with proteins of plasma makes 80%.

After use of drug in the form of capsules active agent approximately for 85% is absorbed in a digestive tract. Extent of communication with proteins of plasma – about 80%. The maximum concentration in plasma is observed approximately 5 hours later. An elimination half-life – from 3,3 to 7,6 hours.

Drug mainly in a liver is split. The main metabolite – hydroxylated derivative. About 60% of active agent and metabolites are excreted by kidneys. The rest is removed through intestines in the form of metabolites.

At patients at advanced age, and also with a heavy liver/renal failure the elimination half-life is increased at use of all forms of release.

Medicine is capable to get through GEB and a placental barrier.

Relative bioavailability of capsules in comparison with solution – about 95%.

Indications to use

It is applied at arterial hypertension in heavy degree, hypertensive crisis, the managed arterial hypertension in time or after surgical interventions, refractory hypertensia.


Ebrantil in the form of solution it is impossible to apply at:

  • hypersensitivity to its components;
  • the opened Botallovy Canal;
  • breastfeeding;
  • pregnancies;
  • aortal stenosis;
  • children's age.

With care it can be appointed to patients of advanced age, and also in case of disturbance of functions of livers/kidneys and a hypovolemia.

Capsules are prohibited to reception at:

  • hypersensitivity to their components;
  • pregnancies;
  • breastfeeding;
  • children's age;
  • intolerance of fructose;
  • syndrome of disturbance of absorption of glucose or galactose;
  • deficit of invertase or isomaltase.

With care are appointed in case of problems with functions of a liver, chronic heart failure, embolism of a pulmonary artery, a renal failure (in average or heavy degree), a stenosis of the aortal/mitral valve, disturbances of contractility of a myocardium because of diseases of a cordial bag. Patients at advanced age also have to take capsules with caution.

Side effects

Use of this medicine can provoke the following side effects: fatigue, dyspepsia, dryness in a mouth, heartbeat, tachycardia, stethalgias, bradycardia, orthostatic hypotension, vomiting, diarrhea, an allergy, a nose congestion, sleeplessness.

In rare instances there is arterial hypotonia, thrombocytopenia, feeling of concern, a priapism, a nephropathy, a nephrotic syndrome, reversible increase of activity of enzymes of a liver, generalized hypostases, an urine incontience, the speeded-up urination.

At fast pressure decrease after administration of solution dizziness, a headache, nausea are possible. As a rule, these manifestations take place within several minutes.

If side reactions have difficult character and do not pass, it is necessary to stop therapy.

Application instruction of Ebrantil (Way and dosage)

Solution is entered struyno or by means of long infusion in situation "lying".

At hypertensive crisis, refractory hypertensia and heavy degree of arterial hypertension two schemes of treatment are possible:

  • Intravenous administration on 10-15 mg slowly, constantly controlling arterial pressure. Its decrease is expected within the first five minutes. Repeated infusion depending on effect is possible.
  • The drug is administered intravenously kapelno or by continuous infusion by means of the perfused pump. 250 mg of drug are dissolved in 500 ml of solution for internal introduction.

Initial rate of administering of at most 2 mg a minute is recommended.

Rate of administering kapelno directly depends on pressure indicators. Solution for drop infusion is intended for maintenance of the ABP.

For controlled pressure decrease continuous infusion by means of the perfused pump or introduction kapelno is carried out to time or after surgical interventions.

Give one intravenous injection of drug (25 mg). If pressure decreases later a couple of minutes, do infusion for stabilization of the ABP (in an initial dosage to 6 mg 1-2 minutes, then gradually the dose is reduced). In cases when pressure did not decrease, one more injection in a dosage of 25 mg is shown. If after two minutes of the ABP decreases, do infusion for stabilization of the ABP. In cases when pressure does not decrease after the second prick, it is shown slow in/in administration of drug (50 mg). Only then do infusion for stabilization of the ABP.

The initial dosage for elderly patients can be lowered.

Injections can be single or repeated. Pricks can be combined with drop infusion. If arterial pressure increases, it is possible to carry out parenteral therapy once again.

Tablets Ebrantil are not issued, the application instruction of capsules recommends to accept them in the morning and in the evening during food, at the same time washing down with a liquid quantity.

Exact dosages are selected in an individual order.

The application instruction of Ebrantil reports that on one capsule (30 mg) 2 times a day usually accept. If there is a need, the dosage is raised to 120 mg.

The day dose should not exceed 180 mg (divided into 2 receptions).

At advanced age or with problems of function of livers/kidneys decrease in a dosage depending on indicators of pressure and work of livers/kidneys can be necessary for patients.


At overdose dizziness, increased fatigue, an orthostatic collapse, block are possible.

At sharp lowering of arterial pressure the patient needs to raise a few legs and to start infusional therapy for increase of OTsK. In rare instances intravenous administration of catecholamines can be necessary.

If there was an overdose by capsules, within the first four hours the gastric lavage is possible, can also appoint reception of absorbent carbon. Symptomatic treatment.


Hypotensive properties of an urapidil can amplify at a combination to alpha adrenoblockers or other hypotensive drugs, and also in case of reception of ethanol and at disorders of work of a gastrointestinal tract (nausea, vomiting).

If earlier other hypotensive medicines were applied, Ebrantil it is possible to use only after a while. Dosages of drug are respectively adjusted.

It is necessary to appoint simultaneous use of capsules with Cimetidinum with care. Such combination can lead to increase of the maximum concentration of an urapidil in plasma for 15%.

Terms of sale

Drug according to the recipe is released.

Storage conditions

Optimum temperature is up to 25 °C. To protect from children.

Period of validity

Period of validity of this medicine – 2 years. It is impossible to use drug after this time.


Opinions on this drug generally positive. Its efficiency is noted not only by patients, but also specialists, including emergency doctors who happen to put often this medicine into practice.

Ebrantil's price where to buy

Ebrantil's price depends on a release form. The cost of ampoules is from about 750 to 960 rubles. And Ebrantil's price in capsules from 262 to 310 rubles.


  • Ebrantil solution for in/in introductions 5mg/ml 10 ml No. 5 ampulynycomed
  • Ebrantil solution for in/in introductions 5mg/ml 5 ml No. 5 ampulynycomed
  • Ebrantil of 30 mg No. 30 kapsulynycomed
  • Ebrantil of 60 mg No. 30 kapsulynycomed
to show still


  • Ebrantilnycomed Oranienburg (Germany)
  • Ebrantilnycomed (Germany)
  • Ebrantilnycomed (Germany)


  • Ebrantil kaps. 30 mg No. 50nikomed
  • Ebrantil kaps. 30 mg No. 50nikomed
  • Ebrantil kaps. 30 mg No. 50nikomed


  • Ebrantil of 30 mg No. 30 kaps.prolong.
to show still
Section: Cardiovascular
PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before medicine use Ebrantil surely consult with the attending physician.